Aprea Therapeutics (NASDAQ:APRE) Stock Price Down 1.7%

Aprea Therapeutics, Inc. (NASDAQ:APRE)’s stock price traded down 1.7% on Monday . The company traded as low as $5.25 and last traded at $5.26. 3,460 shares traded hands during mid-day trading, a decline of 87% from the average session volume of 27,349 shares. The stock had previously closed at $5.35.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Aprea Therapeutics in a research note on Tuesday, March 26th. Wedbush upped their target price on Aprea Therapeutics from $9.00 to $11.00 and gave the company an “outperform” rating in a research report on Wednesday, March 27th.

Aprea Therapeutics Price Performance

The stock has a market cap of $28.56 million, a P/E ratio of -1.32 and a beta of 1.08. The stock’s fifty day simple moving average is $6.24 and its 200-day simple moving average is $5.25.

Aprea Therapeutics (NASDAQ:APRE) last released its quarterly earnings results on Tuesday, March 26th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.36). The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.33 million. Analysts forecast that Aprea Therapeutics, Inc. will post -2.38 EPS for the current year.

Insider Activity at Aprea Therapeutics

In other news, Director Bernd R. Seizinger acquired 6,860 shares of the business’s stock in a transaction dated Wednesday, March 13th. The stock was acquired at an average price of $7.29 per share, for a total transaction of $50,009.40. Following the completion of the acquisition, the director now directly owns 33,685 shares in the company, valued at approximately $245,563.65. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have purchased 9,870 shares of company stock worth $71,952 over the last quarter. 20.90% of the stock is currently owned by company insiders.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers.